---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-028121"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:30:28.703902+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kiora receives Nasdaq deficiency notice for bid price below $1.00; CFO resigns

## Summary
- Nasdaq notified Kiora on Feb 23, 2022 that its stock closed below $1.00 for 30 consecutive business days.
- Company has 180 days (until Aug 22, 2022) to regain compliance by closing >= $1.00 for at least 10 consecutive trading days.
- CFO Sarah Romano resigned effective Feb 25, 2022; Corporate Controller Michael Meluzio appointed as principal financial and accounting officer.
- Kiora evaluating options to regain compliance; may seek additional 180-day period if eligible.

## SEC filing metadata
- accession: 0001104659-22-028121
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000110465922028121/0001104659-22-028121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000110465922028121/tm227887d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-028121
- JSON: https://secwatch.observer/filing/0001104659-22-028121.json
- Plain text: https://secwatch.observer/filing/0001104659-22-028121.txt

## Key facts
- Executive change
  Sarah Romano resigned as Chief Financial Officer at KIORA PHARMACEUTICALS INC.
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Sarah Romano resigned as Chief Financial Officer of the Company effective as of February 25, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000110465922028121/0001104659-22-028121-index.htm
- Executive change
  Michael Meluzio was appointed as principal financial officer and principal accounting officer at KIORA PHARMACEUTICALS INC.
  - Action: appointed
  - Role: principal financial officer and principal accounting officer
  source text: the Company appointed Michael Meluzio, CPA, the Corporate Controller of the Company, as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000110465922028121/0001104659-22-028121-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.